TY - JOUR
T1 - A randomized controlled trial protocol comparing the feeds of fresh versus frozen mother's own milk for preterm infants in the NICU
AU - Sun, Huiqing
AU - Cao, Yun
AU - Han, Shuping
AU - Cheng, Rui
AU - Liu, Ling
AU - Liu, Jiangqin
AU - Xia, Shiwen
AU - Zhang, Jiajie
AU - Li, Zhankui
AU - Cheng, Xiuyong
AU - Yang, Chuanzhong
AU - Pan, Xinnian
AU - Li, Long
AU - Ding, Xin
AU - Wang, Rensheng
AU - Wu, Mingyuan
AU - Li, Xiaoying
AU - Shi, Liping
AU - Xu, Falin
AU - Yu, Fengqin
AU - Pan, Jiahua
AU - Zhang, Xiaolan
AU - Li, Li
AU - Yang, Jie
AU - Li, Mingxia
AU - Yan, Changhong
AU - Zhou, Qi
AU - Lu, Jiao
AU - Wei, Mou
AU - Wang, Laishuan
AU - Yang, Ling
AU - Ye, Xiang Y.
AU - Unger, Sharon
AU - Kakulas, Foteini
AU - Lee, Shoo K.
PY - 2020/2/11
Y1 - 2020/2/11
N2 - Background: Necrotizing enterocolitis (NEC) is the leading cause of death among preterm infants born at < 30 weeks' gestation. The incidence of NEC is reduced when infants are fed human milk. However, in many neonatal intensive care units (NICUs), it is standard practice to freeze and/or pasteurize human milk, which deactivates bioactive components that may offer additional protective benefits. Indeed, our pilot study showed that one feed of fresh mother's own milk per day was safe, feasible, and can reduce morbidity in preterm infants. To further evaluate the benefits of fresh human milk in the NICU, a randomized controlled trial is needed. Methods: Our prospective multicenter, double-blinded, randomized, controlled trial will include infants born at < 30 weeks' gestation and admitted to one of 29 tertiary NICUs in China. Infants in the intervention (fresh human milk) group (n = 1549) will receive at least two feeds of fresh human milk (i.e., within 4 h of expression) per day from the time of enrollment until 32 weeks' corrected age or discharge to home. Infants in the control group (n = 1549) will receive previously frozen human milk following the current standard protocols. Following informed consent, enrolled infants will be randomly allocated to the control or fresh human milk groups. The primary outcome is the composite outcome mortality or NEC ≥ stage 2 at 32 weeks' corrected age, and the secondary outcomes are mortality, NEC ≥ stage 2, NEC needing surgery, late-onset sepsis, retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), weight gain, change in weight, increase in length, increase in head circumference, time to full enteral feeds, and finally, the number and type of critical incident reports, including feeding errors. Discussion: Our double-blinded, randomized, controlled trial aims to examine whether fresh human milk can improve infant outcomes. The results of this study will impact both Chinese and international medical practice and feeding policy for preterm infants. In addition, data from our study will inform changes in health policy in NICUs across China, such that mothers are encouraged to enter the NICU and express fresh milk for their infants.
AB - Background: Necrotizing enterocolitis (NEC) is the leading cause of death among preterm infants born at < 30 weeks' gestation. The incidence of NEC is reduced when infants are fed human milk. However, in many neonatal intensive care units (NICUs), it is standard practice to freeze and/or pasteurize human milk, which deactivates bioactive components that may offer additional protective benefits. Indeed, our pilot study showed that one feed of fresh mother's own milk per day was safe, feasible, and can reduce morbidity in preterm infants. To further evaluate the benefits of fresh human milk in the NICU, a randomized controlled trial is needed. Methods: Our prospective multicenter, double-blinded, randomized, controlled trial will include infants born at < 30 weeks' gestation and admitted to one of 29 tertiary NICUs in China. Infants in the intervention (fresh human milk) group (n = 1549) will receive at least two feeds of fresh human milk (i.e., within 4 h of expression) per day from the time of enrollment until 32 weeks' corrected age or discharge to home. Infants in the control group (n = 1549) will receive previously frozen human milk following the current standard protocols. Following informed consent, enrolled infants will be randomly allocated to the control or fresh human milk groups. The primary outcome is the composite outcome mortality or NEC ≥ stage 2 at 32 weeks' corrected age, and the secondary outcomes are mortality, NEC ≥ stage 2, NEC needing surgery, late-onset sepsis, retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), weight gain, change in weight, increase in length, increase in head circumference, time to full enteral feeds, and finally, the number and type of critical incident reports, including feeding errors. Discussion: Our double-blinded, randomized, controlled trial aims to examine whether fresh human milk can improve infant outcomes. The results of this study will impact both Chinese and international medical practice and feeding policy for preterm infants. In addition, data from our study will inform changes in health policy in NICUs across China, such that mothers are encouraged to enter the NICU and express fresh milk for their infants.
KW - Breast milk, Preterm, Necrotizing enterocolitis, Neonatal intensive care unit (NICU)
UR - https://www.scopus.com/pages/publications/85079337126
U2 - 10.1186/s13063-019-3981-4
DO - 10.1186/s13063-019-3981-4
M3 - Article
C2 - 32046760
AN - SCOPUS:85079337126
SN - 1745-6215
VL - 21
JO - Trials
JF - Trials
IS - 1
M1 - 170
ER -